Over the last 7 days, the United States market has risen by 3.0%, contributing to a remarkable 25% increase over the past year, with earnings expected to grow by 15% per annum in the coming years. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain underappreciated can be key to uncovering hidden opportunities in your investment portfolio.
Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
---|---|---|---|---|
Eagle Financial Services | 170.75% | 12.30% | 1.92% | ★★★★★★ |
Morris State Bancshares | 10.20% | -0.28% | 6.97% | ★★★★★★ |
Wilson Bank Holding | NA | 7.87% | 8.22% | ★★★★★★ |
Omega Flex | NA | 0.39% | 2.57% | ★★★★★★ |
Cashmere Valley Bank | 15.51% | 5.80% | 3.51% | ★★★★★★ |
Teekay | NA | -3.71% | 60.91% | ★★★★★★ |
Parker Drilling | 46.05% | 0.86% | 52.25% | ★★★★★★ |
ASA Gold and Precious Metals | NA | 7.11% | -35.88% | ★★★★★☆ |
FRMO | 0.08% | 38.78% | 45.85% | ★★★★★☆ |
Pure Cycle | 5.15% | -2.61% | -6.23% | ★★★★★☆ |
Click here to see the full list of 261 stocks from our US Undiscovered Gems With Strong Fundamentals screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Value Rating: ★★★★★★
Overview: Viemed Healthcare, Inc. offers home medical equipment and post-acute respiratory healthcare services across the United States, with a market capitalization of $316.55 million.
Operations: Viemed generates revenue primarily from its Sleep and Respiratory Disorders Sector, which accounts for $214.30 million. The company's net profit margin has shown variability over recent periods.
Viemed Healthcare, with its focus on ventilator and sleep therapy services, has shown robust performance in recent quarters. The company reported third-quarter sales of US$58 million, up from US$49.4 million the previous year, while net income increased to US$3.88 million from US$2.92 million. Earnings per share rose to US$0.10 from US$0.08 for the same period last year, reflecting a positive trend in profitability despite challenges like regulatory reliance and capital expenditures for equipment replacements. With a debt-to-equity ratio reduced to 3.5% over five years and strong earnings growth outpacing the industry at 13%, Viemed seems poised for continued expansion supported by its proprietary Engage platform and potential M&A activities.
Simply Wall St Value Rating: ★★★★★★
Overview: First Bank offers a range of banking products and services to small to mid-sized businesses and individuals, with a market capitalization of $346.02 million.
Operations: Revenue from community banking amounts to $123.43 million.
Earnings for First Bank surged by 85.6% over the past year, significantly outpacing the banking industry's -9.9%. With total assets of US$3.8 billion and equity at US$402.1 million, it demonstrates a strong financial footing. The bank's allowance for bad loans stands robustly at 312%, indicating prudent risk management, while customer deposits form 91% of its low-risk funding sources. Shares are trading at a notable discount to estimated fair value, suggesting potential investment appeal. Recent dividend affirmations and earnings announcements underscore confidence in future performance with net income reaching US$42.24 million for 2024 compared to US$20.9 million previously.
Simply Wall St Value Rating: ★★★★☆☆
Overview: Carter Bankshares, Inc. is the bank holding company for Carter Bank & Trust, offering a range of banking products and services in the United States with a market cap of $404.68 million.
Operations: Carter Bankshares generates revenue primarily through interest income from loans and investments, alongside fees from banking services. The company's net profit margin is 22.5%, reflecting its efficiency in managing costs relative to its revenue streams.
Carter Bankshares, with total assets of US$4.7 billion and equity of US$384.3 million, is making waves despite its challenges. Holding deposits worth US$4.2 billion and loans totaling US$3.5 billion, it operates with a net interest margin of 2.9%. However, the bank faces a high level of bad loans at 8%, paired with an insufficient allowance for these loans at just 28%. On the upside, Carter's earnings grew by 5.8% last year, outpacing the industry average decline of -9.9%, while trading significantly below its estimated fair value by 56.7%.
Examine Carter Bankshares' past performance report to understand how it has performed in the past.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:VMD NasdaqGM:FRBA and NasdaqGS:CARE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。